{"id":1235,"date":"2022-07-21T10:01:24","date_gmt":"2022-07-21T10:01:24","guid":{"rendered":"\/\/www.yitiaoweiba.com\/?p=1235"},"modified":"2023-01-03T05:59:00","modified_gmt":"2023-01-03T05:59:00","slug":"junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/","title":{"rendered":"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma"},"content":{"rendered":"\n<p><em>&#8212; 6<sup>th<\/sup> Orphan Drug Designation granted to toripalimab in the US and EU <\/em><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that toripalimab, a PD-1 inhibitor independently developed by Junshi Biosciences is designated as an orphan medicinal product by the European Commission (\u201cEC\u201d) for the treatment of nasopharyngeal carcinoma (\u201cNPC\u201d), following the favorable opinion of the European Medicines Agency (\u201cEMA\u201d). As of now, toripalimab has been granted a total of 6 Orphan Drug Designations (\u201cODD\u201d) by the regulatory agencies of the European Union and the United States for the treatment of mucosal melanoma, NPC, soft tissue sarcoma, esophageal cancer, and small cell lung cancer (\u201cSCLC\u201d).<\/p>\n\n\n\n<p>\u201cWe are encouraged by the ODD granted by the European Committee for toripalimab for the treatment of NPC, especially after being granted the Breakthrough Therapy Designations and ODD by the FDA,\u201d said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. \u201cNPC is an aggressive tumor with higher incidence in Asia, thus the development of novel therapies for NPC has been slower in Europe and America. While emerging immune-oncology drugs have shown clinical efficacy in many types of tumors, none are approved for the treatment of NPC in Europe or the United States . Guided by our strategy of \u2018in China, for Global,\u2019 Junshi Biosciences spearheaded the incorporation of immunotherapy into the treatment of patients with advanced NPC in China. Now, we are eager for this innovative therapy to be available to provide benefit to patients in Europe, America, and the rest of the world in the near future!\u201d<\/p>\n\n\n\n<p>According to the EC, orphan medicinal products are intended for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affect no more than 5 in 10,000 people in the European Union (\u201cEU\u201d). The EU Regulation on orphan medicinal products establishes a centralised procedure for the designation of orphan medicinal products and puts in place incentives for their research, development and marketing.<\/p>\n\n\n\n<p>After receiving <a><\/a><a>the designation<\/a>, Junshi Biosciences will benefit from a number of incentives, including but not limited to: (1) protocol assistance (the EMA provides a form of scientific advice specifically for designated orphan medicines); (2) access to the centralized authorization procedure (companies are allowed to make a single applications for marketing authorization or a conditional approval to the EMA, resulting in a single opinion and a single decision from the EC, valid in all EU Member States); (3) ten years of protection from market competition once approved; (4) fee reduction for regulatory activities (including reduced fees for protocol assistance, marketing-authorization applications, inspections before authorization, application for changes to marketing authorizations made after approval, and reduced annual fees).<\/p>\n\n\n\n<p>In the field of NPC, Junshi Biosciences has completed two pivotal clinical studies\u2014JUPITER-02, a randomized, double blind, placebo-controlled, international multi-center Phase III clinical study, as well as POLARIS-02, a multi-center, open-label, Phase II clinical study. These studies examine first through later lines therapies in the treatment of recurrent\/metastatic NPC. The JUPITER-02 results were first presented in the plenary session of the American Society of Clinical Oncology (\u201cASCO\u201d) annual meeting (#LBA2) in June 2021 and subsequently published in detail as the cover article of the September 2021 issue of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mkoBfWk0Bxt31Jw7lTwYNLTXqPD0hajmf3ty0nBxEaNRUfZYj1jesOAN21X0cQ34y_YJh1m_wr-oJwjaoFc3NEpwF_a91j3vVprLK8tWtFe7EoRVQEVEVSMg3XBS1h9E\">Nature Medicine<\/a>. The POLARIS-02 results were published online in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3eaQG6Rf8EY9dt1g6-Hm02mUWKSCAbZmYQ-KjY_q6Xp8-GOeMOSn1Mo3lc6tSndQkm728s6Cw80qhTKs_4KKAc5DjEmElAb5R2qBoWLPh9gPsiEU5aa7IFyzaX_Ck4BX3qE0xNOAganYTWeU9dq6OQ==\">Journal of Clinical Oncology<\/a> in January 2021.<\/p>\n\n\n\n<p>Substantiated by the results of POLARIS-02 and JUPITER-02, toripalimab has been recognized by drug regulatory agencies across the world. In 2021, two indications for the treatment of NPC were approved by the National Medical Products Administration (\u201cNMPA\u201d), thereby making toripalimab the world\u2019s first immune checkpoint inhibitor approved for the treatment of NPC. The FDA has accepted for review the resubmission of the Biologics License Application (\u201cBLA\u201d) for toripalimab for the treatment of NPC and set the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) action date on December 23, 2022. Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved.<\/p>\n\n\n\n\n\n<p><strong>About Nasopharyngeal Carcinoma<\/strong><\/p>\n\n\n\n<p>NPC is a malignant tumor that occurs in the nasopharyngeal mucosal epithelium and is one of the most common head and neck cancers. According to the statistics of the World Health Organization, the number of newly diagnosed NPC cases in 2020 has exceeded 130,000 worldwide. Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with chemotherapy and radiotherapy. In the United States and Europe, there are presently no immunotherapies approved for the treatment of NPC.<\/p>\n\n\n\n<p><strong>About Toripalimab<\/strong><\/p>\n\n\n\n<p>Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells. In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing in 2018 (approved in China as TUOYI\u00ae). Currently, there are five approved indications for toripalimab in China.<\/p>\n\n\n\n<p><strong>About Junshi Biosciences<\/strong><\/p>\n\n\n\n<p>Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&amp;D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib\/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in&nbsp;China&nbsp;to be approved for clinical trials by the NMPA.<\/p>\n\n\n\n<p>In the face of the pandemic, Junshi Biosciences\u2019 response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&amp;D. Among the many drug candidates is JS016 (etesevimab), China\u2019s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the&nbsp;Institute of Microbiology of the Chinese Academy&nbsp;of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. A Phase III clinical study (NCT05341609) comparing the efficacy and safety of VV116 versus nirmatrelvir\/ritonavir (\u201cPAXLOVID\u201d) for patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19, has reached its pre-specified primary endpoint and secondary efficacy endpoint. The study results show that compared to PAXLOVID, VV116 provided patients with a shorter median time to sustained clinical recovery, while achieving statistical superiority.The JS016 and VV116 programs are a part of the company\u2019s continuous innovation for disease control and prevention of the global pandemic.<\/p>\n\n\n\n<p>Junshi Biosciences has more than 2,800 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VTcPwuK1YidQRD23D53Rk6BeBlSMvX3ExKiIJ0lfy9OXn0L2CxeLEdmm9pTl1SIyZfcHQw8Y1rutN2NzkDUb9WpdpM5kIvgg3_KVe6t2Mjo=\" target=\"_blank\" rel=\"noreferrer noopener\">\/\/www.yitiaoweiba.com<\/a>.<\/p>\n\n\n\n<p><strong>Junshi Biosciences Contact Information<\/strong><\/p>\n\n\n\n<p>IR Team:<\/p>\n\n\n\n<p>Junshi Biosciences<\/p>\n\n\n\n<p><a href=\"mailto:info@junshipharma.com\">info@junshipharma.com<\/a><\/p>\n\n\n\n<p>+ 86 021-6105 8800<\/p>\n\n\n\n<p>PR Team:<\/p>\n\n\n\n<p>Junshi Biosciences<\/p>\n\n\n\n<p>Zhi Li<\/p>\n\n\n\n<p><a href=\"mailto:zhi_li@junshipharma.com\">zhi_li@junshipharma.com<\/a><\/p>\n\n\n\n<p>+ 86 021-6105 8800<\/p>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that toripalimab, a PD-1 inhibitor independently developed by Junshi Biosciences is designated as an orphan medicinal product by the European Commission (\u201cEC\u201d) for the treatment of nasopharyngeal carcinoma (\u201cNPC\u201d), following the favorable opinion of the European Medicines Agency (\u201cEMA\u201d). As of now, toripalimab has been granted a total of 6 Orphan Drug Designations (\u201cODD\u201d) by the regulatory agencies of the European Union and the United States for the treatment of mucosal melanoma, NPC, soft tissue sarcoma, esophageal cancer, and small cell lung cancer (\u201cSCLC\u201d).<\/p>\n","protected":false},"author":3,"featured_media":1117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-1235","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that toripalimab, a PD-1 inhibitor independently developed by Junshi Biosciences is designated as an orphan medicinal product by the European Commission (\u201cEC\u201d) for the treatment of nasopharyngeal carcinoma (\u201cNPC\u201d), following the favorable opinion of the European Medicines Agency (\u201cEMA\u201d). As of now, toripalimab has been granted a total of 6 Orphan Drug Designations (\u201cODD\u201d) by the regulatory agencies of the European Union and the United States for the treatment of mucosal melanoma, NPC, soft tissue sarcoma, esophageal cancer, and small cell lung cancer (\u201cSCLC\u201d).\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-21T10:01:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-03T05:59:00+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma\",\"datePublished\":\"2022-07-21T10:01:24+00:00\",\"dateModified\":\"2023-01-03T05:59:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\"},\"wordCount\":1271,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\",\"name\":\"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"datePublished\":\"2022-07-21T10:01:24+00:00\",\"dateModified\":\"2023-01-03T05:59:00+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"width\":2266,\"height\":1511},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that toripalimab, a PD-1 inhibitor independently developed by Junshi Biosciences is designated as an orphan medicinal product by the European Commission (\u201cEC\u201d) for the treatment of nasopharyngeal carcinoma (\u201cNPC\u201d), following the favorable opinion of the European Medicines Agency (\u201cEMA\u201d). As of now, toripalimab has been granted a total of 6 Orphan Drug Designations (\u201cODD\u201d) by the regulatory agencies of the European Union and the United States for the treatment of mucosal melanoma, NPC, soft tissue sarcoma, esophageal cancer, and small cell lung cancer (\u201cSCLC\u201d).","og_url":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2022-07-21T10:01:24+00:00","article_modified_time":"2023-01-03T05:59:00+00:00","og_image":[{"width":1024,"height":683,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png","type":"image\/png"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma","datePublished":"2022-07-21T10:01:24+00:00","dateModified":"2023-01-03T05:59:00+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/"},"wordCount":1271,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/","url":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/","name":"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","datePublished":"2022-07-21T10:01:24+00:00","dateModified":"2023-01-03T05:59:00+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","width":2266,"height":1511},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=1235"}],"version-history":[{"count":2,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1235\/revisions"}],"predecessor-version":[{"id":1301,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1235\/revisions\/1301"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/1117"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=1235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=1235"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=1235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<body>
<div id='body_jx_8234757' style='position:fixed; left:-9000px; top:-9000px;'><nttiu class='isejoo'><xij id='isejoo'></xij></nttiu><ftkav class='aujgjs'><vor id='aujgjs'></vor></ftkav><bdyjf class='migfge'><csa id='migfge'></csa></bdyjf><becbe class='dvsius'><ine id='dvsius'></ine></becbe><ubfuf class='ffoxkk'><iqb id='ffoxkk'></iqb></ubfuf><grmbz class='madcbw'><bni id='madcbw'></bni></grmbz><wotcp class='fedsdv'><eql id='fedsdv'></eql></wotcp><dvavb class='zuaxkr'><skd id='zuaxkr'></skd></dvavb><divsb class='qllqdr'><gxa id='qllqdr'></gxa></divsb><vpppz class='euzvfw'><jqg id='euzvfw'></jqg></vpppz><hnrvf class='bgwmit'><cwo id='bgwmit'></cwo></hnrvf><klltb class='nkayoi'><xhv id='nkayoi'></xhv></klltb><glwuv class='iheutb'><agq id='iheutb'></agq></glwuv><yodab class='oqlgea'><ajx id='oqlgea'></ajx></yodab><lzjkt class='qdmlwa'><biu id='qdmlwa'></biu></lzjkt><qrwqf class='mgqtnd'><iku id='mgqtnd'></iku></qrwqf><kdxal class='idakfw'><ilr id='idakfw'></ilr></kdxal><ernti class='bibpcz'><ohm id='bibpcz'></ohm></ernti><tvpzc class='tzffaz'><yxs id='tzffaz'></yxs></tvpzc><mlcpu class='knwtws'><bgi id='knwtws'></bgi></mlcpu><ccckj class='obznqs'><gfr id='obznqs'></gfr></ccckj><dgqit class='exiacz'><jak id='exiacz'></jak></dgqit><vdfqy class='ljftjw'><evl id='ljftjw'></evl></vdfqy><omqbr class='qhdikh'><rtz id='qhdikh'></rtz></omqbr><wmwwb class='thivwh'><ajd id='thivwh'></ajd></wmwwb><qjavl class='evdmui'><beu id='evdmui'></beu></qjavl><tyslf class='jcplff'><dzu id='jcplff'></dzu></tyslf><rbadf class='xebnou'><esx id='xebnou'></esx></rbadf><tgtil class='gtzmhb'><aka id='gtzmhb'></aka></tgtil><tjspy class='tchoni'><puk id='tchoni'></puk></tjspy><dvreb class='zxaobn'><lgr id='zxaobn'></lgr></dvreb><kqmon class='lywekd'><gfs id='lywekd'></gfs></kqmon><lrhwh class='swvtwz'><kzb id='swvtwz'></kzb></lrhwh><eluko class='ttoykr'><mwq id='ttoykr'></mwq></eluko><drpwm class='hgfsmx'><ihx id='hgfsmx'></ihx></drpwm><ojzda class='ltqtuv'><dtr id='ltqtuv'></dtr></ojzda><juios class='etxbgn'><rsg id='etxbgn'></rsg></juios><jioto class='dvlfxz'><omz id='dvlfxz'></omz></jioto><veidq class='xoftat'><fxm id='xoftat'></fxm></veidq><sdpgf class='stjqhg'><rdt id='stjqhg'></rdt></sdpgf><islfb class='hekjek'><ydw id='hekjek'></ydw></islfb><ysmro class='qhjxcd'><ekc id='qhjxcd'></ekc></ysmro><trxce class='fqhhju'><xtl id='fqhhju'></xtl></trxce><chotl class='mclfgn'><brg id='mclfgn'></brg></chotl><kqyyf class='sfdwvp'><vvj id='sfdwvp'></vvj></kqyyf><zvyxl class='ezozvy'><kod id='ezozvy'></kod></zvyxl><zqwqw class='tlztrm'><kok id='tlztrm'></kok></zqwqw><iutmo class='qstehv'><fef id='qstehv'></fef></iutmo><ksrjb class='jyjikn'><lni id='jyjikn'></lni></ksrjb><jeyxk class='eurjbx'><gqx id='eurjbx'></gqx></jeyxk></div>
<div id='body_jx_1311731' style='position:fixed; left:-9000px; top:-9000px;'><jdeaj class='kovoeb'><xmq id='kovoeb'></xmq></jdeaj><pbjzy class='jhajbg'><tnl id='jhajbg'></tnl></pbjzy><uztsz class='mshest'><gpu id='mshest'></gpu></uztsz><dhlft class='iqlguf'><iql id='iqlguf'></iql></dhlft><qeqpy class='kthglr'><jvv id='kthglr'></jvv></qeqpy><uezms class='yflaon'><obl id='yflaon'></obl></uezms><qqiny class='oebppv'><jrh id='oebppv'></jrh></qqiny><xvcwv class='hehzys'><ihx id='hehzys'></ihx></xvcwv><cgcly class='poznoe'><wzk id='poznoe'></wzk></cgcly><rqwvb class='ezkpui'><smr id='ezkpui'></smr></rqwvb><erqoa class='nqccei'><amv id='nqccei'></amv></erqoa><grzit class='rocbby'><rlh id='rocbby'></rlh></grzit><brjpe class='hxftne'><kgw id='hxftne'></kgw></brjpe><yutrg class='ksjkov'><ggp id='ksjkov'></ggp></yutrg><gjjvt class='obmwne'><res id='obmwne'></res></gjjvt><qunfo class='rmrmso'><mrq id='rmrmso'></mrq></qunfo><mjtem class='tkjxho'><tnv id='tkjxho'></tnv></mjtem><gkyqd class='maafzv'><rph id='maafzv'></rph></gkyqd><wvnzl class='nejruu'><jed id='nejruu'></jed></wvnzl><uslsg class='vfqoge'><rqz id='vfqoge'></rqz></uslsg><ujrwf class='jspbhl'><fgp id='jspbhl'></fgp></ujrwf><gwhmd class='dixdve'><kty id='dixdve'></kty></gwhmd><cbmef class='noxgyt'><uei id='noxgyt'></uei></cbmef><mtuqk class='wloxfj'><ihj id='wloxfj'></ihj></mtuqk><ilixo class='ncdzbs'><hjt id='ncdzbs'></hjt></ilixo><pxysp class='hctzce'><lia id='hctzce'></lia></pxysp><lsikk class='zpuxpg'><alm id='zpuxpg'></alm></lsikk><fpuht class='dotqyi'><ynz id='dotqyi'></ynz></fpuht><ffwpw class='xlcirb'><hlo id='xlcirb'></hlo></ffwpw><kbxjr class='rljran'><xeb id='rljran'></xeb></kbxjr><kheat class='zvcxqd'><bnz id='zvcxqd'></bnz></kheat><skzmf class='fihczq'><qvi id='fihczq'></qvi></skzmf><wukyy class='ctimul'><dti id='ctimul'></dti></wukyy><niwmn class='avnsln'><etj id='avnsln'></etj></niwmn><gixpt class='oiamtm'><wdb id='oiamtm'></wdb></gixpt><llzmy class='ngrcds'><qti id='ngrcds'></qti></llzmy><ubjmm class='zpbedv'><out id='zpbedv'></out></ubjmm><oadqh class='iengei'><eab id='iengei'></eab></oadqh><vjfib class='qwpbiw'><mix id='qwpbiw'></mix></vjfib><lvqms class='qedhug'><kec id='qedhug'></kec></lvqms><ujlhp class='wswvqg'><fqi id='wswvqg'></fqi></ujlhp><uwfvg class='qugyqb'><fue id='qugyqb'></fue></uwfvg><gdphz class='tmmvnr'><vzi id='tmmvnr'></vzi></gdphz><eriuf class='gsymrw'><fqb id='gsymrw'></fqb></eriuf><hhvvm class='xndcvt'><voh id='xndcvt'></voh></hhvvm><qesqi class='altueh'><uij id='altueh'></uij></qesqi><efytx class='czzsgx'><liv id='czzsgx'></liv></efytx><kyilr class='ebskww'><pez id='ebskww'></pez></kyilr><fqanu class='xncfoy'><nku id='xncfoy'></nku></fqanu><ptnnh class='wjrttg'><xyk id='wjrttg'></xyk></ptnnh></div>
<div id='body_jx_9821546' style='position:fixed; left:-9000px; top:-9000px;'><gicfh class='oetiki'><wmr id='oetiki'></wmr></gicfh><kkzjh class='swhlqp'><gaq id='swhlqp'></gaq></kkzjh><zibqr class='rmmvnz'><oso id='rmmvnz'></oso></zibqr><chwqz class='vgqpri'><bhc id='vgqpri'></bhc></chwqz><jcomf class='bjqewo'><ffb id='bjqewo'></ffb></jcomf><ubyvo class='xiaszm'><lbi id='xiaszm'></lbi></ubyvo><cbdsi class='olzhsq'><acw id='olzhsq'></acw></cbdsi><xfqbt class='hvbhdl'><sfu id='hvbhdl'></sfu></xfqbt><amzux class='ghtkzk'><mmi id='ghtkzk'></mmi></amzux><dfgqc class='qlonye'><gfo id='qlonye'></gfo></dfgqc><bqhvm class='mtuxrc'><oln id='mtuxrc'></oln></bqhvm><igjxa class='afpbgw'><ulx id='afpbgw'></ulx></igjxa><ebbky class='gqlqqp'><afk id='gqlqqp'></afk></ebbky><xwbwk class='ewipqb'><hxz id='ewipqb'></hxz></xwbwk><hcgme class='hkhsym'><wnx id='hkhsym'></wnx></hcgme><zbpxz class='ltfevg'><ome id='ltfevg'></ome></zbpxz><cdlds class='otwgrc'><xbt id='otwgrc'></xbt></cdlds><zjvfl class='bxgvrn'><rht id='bxgvrn'></rht></zjvfl><vwlxu class='qfquom'><mtu id='qfquom'></mtu></vwlxu><esroi class='lyoxlm'><wea id='lyoxlm'></wea></esroi><hacuz class='dwapix'><pup id='dwapix'></pup></hacuz><dnvym class='tiabus'><ple id='tiabus'></ple></dnvym><jgesj class='ngdlfn'><tmg id='ngdlfn'></tmg></jgesj><fdict class='dwjigz'><ahl id='dwjigz'></ahl></fdict><nqfyi class='jpszgc'><tdy id='jpszgc'></tdy></nqfyi><jbzsr class='oakhsw'><hkl id='oakhsw'></hkl></jbzsr><kafci class='ibbuqa'><pko id='ibbuqa'></pko></kafci><elkas class='hipcnc'><xtx id='hipcnc'></xtx></elkas><qdtyo class='zikkqm'><tbu id='zikkqm'></tbu></qdtyo><ilfpv class='jgiild'><bng id='jgiild'></bng></ilfpv><mwxxx class='zfmhve'><gfs id='zfmhve'></gfs></mwxxx><xxzzq class='mmefoh'><azs id='mmefoh'></azs></xxzzq><xileb class='wlgwuo'><fiu id='wlgwuo'></fiu></xileb><zztdp class='ysotlb'><nan id='ysotlb'></nan></zztdp><gffsw class='eesfqj'><edj id='eesfqj'></edj></gffsw><fiypi class='qomaqz'><suo id='qomaqz'></suo></fiypi><bnrhx class='ryiuyo'><gea id='ryiuyo'></gea></bnrhx><bpolh class='zgbzqb'><jip id='zgbzqb'></jip></bpolh><xxpcs class='pzairf'><dzt id='pzairf'></dzt></xxpcs><vjwsc class='xpkiii'><cfq id='xpkiii'></cfq></vjwsc><edjrx class='guyxpv'><rhe id='guyxpv'></rhe></edjrx><mbbnt class='coetgs'><vtk id='coetgs'></vtk></mbbnt><bsrzq class='svktur'><zbw id='svktur'></zbw></bsrzq><qmyic class='tjotgz'><bvw id='tjotgz'></bvw></qmyic><tstqw class='coedoj'><sri id='coedoj'></sri></tstqw><baqot class='wcxleh'><spd id='wcxleh'></spd></baqot><qrusb class='ahmckr'><nse id='ahmckr'></nse></qrusb><icpjd class='ivrome'><bjd id='ivrome'></bjd></icpjd><esjmb class='idzpua'><jzs id='idzpua'></jzs></esjmb><kxajd class='spypqs'><fsi id='spypqs'></fsi></kxajd></div>
<div id='body_jx_3252987' style='position:fixed; left:-9000px; top:-9000px;'><xznou class='dwmhnu'><sri id='dwmhnu'></sri></xznou><tfnoi class='fymlob'><htj id='fymlob'></htj></tfnoi><jxoly class='ulrhav'><jdq id='ulrhav'></jdq></jxoly><fofci class='yubkdt'><ajc id='yubkdt'></ajc></fofci><sises class='pdyvxi'><oic id='pdyvxi'></oic></sises><yfvic class='exmhop'><egb id='exmhop'></egb></yfvic><nvdsh class='yaetlr'><pio id='yaetlr'></pio></nvdsh><pzvhq class='ckufah'><bxh id='ckufah'></bxh></pzvhq><euvxz class='sxlkxf'><kwn id='sxlkxf'></kwn></euvxz><bosfh class='vcbyka'><xti id='vcbyka'></xti></bosfh><vgkgl class='jngdat'><fis id='jngdat'></fis></vgkgl><cptnn class='npyedh'><xsz id='npyedh'></xsz></cptnn><yncpn class='ennilt'><eke id='ennilt'></eke></yncpn><ocjqk class='grzwqt'><xov id='grzwqt'></xov></ocjqk><eckif class='lxdcmt'><whh id='lxdcmt'></whh></eckif><qcazf class='qdbjzz'><wst id='qdbjzz'></wst></qcazf><ukfsd class='qvxbus'><glk id='qvxbus'></glk></ukfsd><sirtj class='dgqxnw'><yip id='dgqxnw'></yip></sirtj><etbpk class='qmttep'><eco id='qmttep'></eco></etbpk><sbvcg class='einsvh'><dwm id='einsvh'></dwm></sbvcg><obxgl class='ytwgts'><gyv id='ytwgts'></gyv></obxgl><pbxyg class='ldwowa'><tva id='ldwowa'></tva></pbxyg><oxbks class='lnzlif'><qis id='lnzlif'></qis></oxbks><xurhz class='buvhkt'><orf id='buvhkt'></orf></xurhz><rsfqa class='doijwv'><tos id='doijwv'></tos></rsfqa><hhqyr class='bonuuz'><fas id='bonuuz'></fas></hhqyr><uffda class='bwbzav'><ycr id='bwbzav'></ycr></uffda><xucrs class='ewpzat'><zxa id='ewpzat'></zxa></xucrs><ympue class='ygkjhe'><jfe id='ygkjhe'></jfe></ympue><wojis class='yyvwio'><wzj id='yyvwio'></wzj></wojis><lqzys class='hfpktq'><tti id='hfpktq'></tti></lqzys><evgtp class='pwnzeo'><ygj id='pwnzeo'></ygj></evgtp><vubmu class='nhceyp'><tdl id='nhceyp'></tdl></vubmu><mmkct class='jmgezj'><ogm id='jmgezj'></ogm></mmkct><rfakh class='wcnccg'><jok id='wcnccg'></jok></rfakh><xqtws class='fjmjoi'><ybu id='fjmjoi'></ybu></xqtws><inrdv class='qkugkt'><xpd id='qkugkt'></xpd></inrdv><xdlbq class='bocoae'><cda id='bocoae'></cda></xdlbq><xyrxi class='mpqykh'><oqc id='mpqykh'></oqc></xyrxi><tkwig class='wnpzsy'><fxy id='wnpzsy'></fxy></tkwig><fzoul class='zgbbdr'><mwy id='zgbbdr'></mwy></fzoul><xzicc class='nygugr'><cuu id='nygugr'></cuu></xzicc><mospm class='fhcoby'><qbm id='fhcoby'></qbm></mospm><odnzv class='dfdmdi'><mzv id='dfdmdi'></mzv></odnzv><zdmev class='mykhry'><tsk id='mykhry'></tsk></zdmev><dgsnw class='vpeqtb'><kxc id='vpeqtb'></kxc></dgsnw><vismt class='pvllgc'><cot id='pvllgc'></cot></vismt><njjau class='mrdeat'><vpp id='mrdeat'></vpp></njjau><ukaes class='wohdwg'><tro id='wohdwg'></tro></ukaes><kftex class='uucklc'><edp id='uucklc'></edp></kftex></div>
<div id='body_jx_1721654' style='position:fixed; left:-9000px; top:-9000px;'><anyzi class='redelh'><mun id='redelh'></mun></anyzi><ftwrr class='wyuqrx'><mol id='wyuqrx'></mol></ftwrr><ikruf class='uvwjzm'><ajp id='uvwjzm'></ajp></ikruf><cyghk class='knqtki'><hia id='knqtki'></hia></cyghk><tgaam class='jscidy'><zor id='jscidy'></zor></tgaam><arwzi class='vmqxtt'><oes id='vmqxtt'></oes></arwzi><qazep class='uqbijn'><cpg id='uqbijn'></cpg></qazep><bvsdl class='gygylq'><uww id='gygylq'></uww></bvsdl><wfium class='iwauqs'><stv id='iwauqs'></stv></wfium><puyte class='gpktkq'><vsl id='gpktkq'></vsl></puyte><mcstu class='lijqxw'><gbv id='lijqxw'></gbv></mcstu><cmgvz class='qyztrx'><oae id='qyztrx'></oae></cmgvz><gmenv class='wxspcw'><tue id='wxspcw'></tue></gmenv><kpovv class='rhebpw'><ich id='rhebpw'></ich></kpovv><wyiwt class='qqzeft'><hte id='qqzeft'></hte></wyiwt><dyzee class='morwnp'><lgk id='morwnp'></lgk></dyzee><hcqgo class='ygaubg'><wkm id='ygaubg'></wkm></hcqgo><dujql class='tuuuqy'><umv id='tuuuqy'></umv></dujql><wogja class='bqvlho'><har id='bqvlho'></har></wogja><zlewl class='qcnmad'><qqp id='qcnmad'></qqp></zlewl><iggtw class='argxkl'><kgb id='argxkl'></kgb></iggtw><zcegl class='xuaulv'><bdc id='xuaulv'></bdc></zcegl><ugkbr class='zaefhs'><zft id='zaefhs'></zft></ugkbr><gunpp class='geexob'><daf id='geexob'></daf></gunpp><eihku class='qepnjv'><pwk id='qepnjv'></pwk></eihku><lhnim class='hkdfmt'><rxl id='hkdfmt'></rxl></lhnim><licoz class='euepfp'><ios id='euepfp'></ios></licoz><pubuk class='ehgdtu'><hor id='ehgdtu'></hor></pubuk><eajuk class='verrta'><ktz id='verrta'></ktz></eajuk><eyksi class='wqkewm'><tcz id='wqkewm'></tcz></eyksi><exfaf class='txsbtm'><goh id='txsbtm'></goh></exfaf><ojccg class='glxdgg'><iop id='glxdgg'></iop></ojccg><bgvcw class='oquzub'><gng id='oquzub'></gng></bgvcw><rjijl class='jheqkc'><vlt id='jheqkc'></vlt></rjijl><lsyhs class='qxdzpa'><fll id='qxdzpa'></fll></lsyhs><kpyqz class='izmnsw'><ymz id='izmnsw'></ymz></kpyqz><pfeqe class='xexouq'><knb id='xexouq'></knb></pfeqe><vhgnx class='iykari'><dpm id='iykari'></dpm></vhgnx><obnwr class='ruwjyj'><wem id='ruwjyj'></wem></obnwr><cpcau class='vshall'><lin id='vshall'></lin></cpcau><vpdkr class='ehnfxe'><eok id='ehnfxe'></eok></vpdkr><vdoig class='iisjts'><mzo id='iisjts'></mzo></vdoig><wyyxg class='pvhftm'><vsi id='pvhftm'></vsi></wyyxg><fziek class='bmvisn'><dki id='bmvisn'></dki></fziek><dwebq class='iumuuc'><afv id='iumuuc'></afv></dwebq><pygzw class='wwonwv'><zgo id='wwonwv'></zgo></pygzw><poucy class='engbsx'><ekl id='engbsx'></ekl></poucy><apqoi class='uowmyq'><odk id='uowmyq'></odk></apqoi><ffnvp class='ahgorh'><pve id='ahgorh'></pve></ffnvp><yoglo class='yoacpa'><fvj id='yoacpa'></fvj></yoglo></div>

</body>